PATIENTS SLIDER

Regenerative Therapy to Heal Diseases of the Retina

Noregen® (CTR-107) is a synthetic protein modeled after norrin, a naturally occurring protein that guides retinal formation in fetal development. It targets the progressive loss of the tiny capillary vessels and promotes their organized re-growth. The ultimate promise is to reverse vision loss in diseases affecting retinal and choroidal blood vessels.

 

Norrin performs these functions in the body:

  • Promotes development of continuous (non-fenestrated) blood vessels
  • Creates blood-retinal-barrier (BRB)
  • Inhibits vascular leakage via transcytosis (pinocytosis)
  • Promotes neurogenesis via the neurovascular unit

 

We’ve found that Noregen® (CTR-107) functions similarly. In mouse models it:

  • Rescues capillary growth. Norrin regrows retinal vessels with a single intravitreal injection.
  • In vivo protects from VEGF insult. Noregen® (CTR-107) treated eyes have reduced leakage and improved vascularization following VEGF insult
  • Activates progenitor stem cells and stimulates both vascular and neuronal growth in appropriate areas. Healthy capillary growth requires neural pathways to guide capillary development.
  • Promotes glial cell growth that is needed for angiogenesis and neurogenesis.
  • Protects and activates resident progenitor cells in the retina following injury.

 

Noregen® (CTR-107) is a unique, novel regenerative, retinal therapeutic that is derived from an endogenous human protein and is backed by solid in vitro and in vivo science. Noregen® (CTR-107) addresses an urgent unmet need in patients with inherited or acquired retinal diseases. There is also exciting potential for expansion of Noregen’s® (CTR-107) therapeutic range beyond retinal diseases.

 

On January 27, 2022 the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for Noregen® (CTR-107), the first potential regenerative therapy for the treatment of Familial Exudative Vitreoretinopathy (FEVR) associated vision loss. Read the press release here.

 

For more information about our collaborative development work with Dr. Kenneth Mitton at Oakland University, click here.

 

For more information regarding our Oakland University partners, click here. 

 

For more information about Noregen® (CTR-107) or our science email us at [email protected]

OUR SCIENCE

As a company dedicated to pursuit of regenerative medicine approaches for sensory-related diseases, Caeregen Therapeutics applies leading-edge science and technologies to the discovery and development of novel therapies to repair, restore, and protect diseased or damaged sensory and neurologic structures.